Investigational drug · Phase 2
MAR002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acromegaly.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MAR002"
First trial start
2026
Jul 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MAR002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acromegaly
Approved drugs for the same conditions: Acromegaly · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "MAR002" as an intervention, largest first.
Marea TherapeuticsIndustry
NCT07641179 · 72 participants (planned) · Start Jul 23, 2026 · Primary completion Aug 2027
Drug: MAR002; Placebo · For: Acromegaly
Sites: Phoenix, Arizona; Columbus, Ohio; San Antonio, Texas
- Study of MAR002 in Healthy MenRecruiting
Marea TherapeuticsIndustry
NCT07195175 · 45 participants (planned) · Start Aug 11, 2025 · Primary completion Jul 2026
Drug: MAR002; Placebo · For: Acromegaly
Sites: Tempe, Arizona
Newest research
PubMed records naming it or its code names, newest first.
- New and emerging pharmacological treatment options for acromegaly: a 2026 update.
Wildemberg LE, Marques NV, Kasuki L, et al. · Expert Opin Pharmacother 2026
- Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly.
Kurylo K, Bouchard PR, Milton MN, et al. · Endocrinology 2026
- What is the future of acromegaly therapy?
Schilbach K, Strasburger CJ · J Clin Endocrinol Metab 2026
- Importance of twitching and surface-associated motility in the virulence of Acinetobacter baumannii.
Corral J, Pérez-Varela M, Sánchez-Osuna M, et al. · Virulence 2021
- Mutations in the β-Subunit of the RNA Polymerase Impair the Surface-Associated Motility and Virulence of Acinetobacter baumannii.
Pérez-Varela M, Corral J, Vallejo JA, et al. · Infect Immun 2017
- Analysis of the role of the LH92_11085 gene of a biofilm hyper-producing Acinetobacter baumannii strain on biofilm formation and attachment to eukaryotic cells.
Álvarez-Fraga L, Pérez A, Rumbo-Feal S, et al. · Virulence 2016
Also in development for Acromegaly
- CAM2029octreotide depotPhase 33 trials
Camurus AB · Polycystic Liver Disease, Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
- SYHX2008Phase 33 trials
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Diagnosed With Acromegaly, Currently in the Active Stage of the Disease, Gastrointestinal Neuroendocrine Pancreatic Tumor, Acromegaly
- Debio 4126Phase 31 trial
Debiopharm International SA · Acromegaly
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.